Hemab Raises $157m To Take Lead Bleeding Disorder Drug Into Pivotal Trial

 
• By Mandy Jackson
  
Hemab will take sutacimig into a pivotal trial in Glanzmann thrombasthenia and deliver Phase II data in Factor VII deficiency in 2026 (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Scrip

More from Financing